Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912

Blood Adv bloodadvances.2024013474.

https://doi.org/10.1182/bloodadvances.2024013474

Published: 2024

Includes: Supplemental data

Journal Articles

Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes

Blood Adv (2024) 8 (5): 1137–1142.

https://doi.org/10.1182/bloodadvances.2023010535

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis

Blood Adv (2023) 7 (19): 5941–5953.

https://doi.org/10.1182/bloodadvances.2022008282

Published: 2023

Includes: Supplemental data

Journal Articles

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Blood Adv (2023) 7 (17): 5000–5013.

https://doi.org/10.1182/bloodadvances.2023009675

Published: 2023

Includes: Supplemental data

Journal Articles

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger

Blood Adv (2023) 7 (2): 196–204.

https://doi.org/10.1182/bloodadvances.2022007791

Published: 2023

Includes: Supplemental data

Journal Articles

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Harry P. Erba, Frederick R. Appelbaum, Richard A. Larson, Theresa H.M. Keegan, Wendy Stock

Blood Adv (2022) 6 (14): 4085–4092.

https://doi.org/10.1182/bloodadvances.2022007197

Published: 2022

Includes: Supplemental data

Journal Articles

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrózek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poiré, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman

Blood Adv (2022) 6 (11): 3433–3439.

https://doi.org/10.1182/bloodadvances.2021006682

Published: 2022

Journal Articles

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A -rearranged AML

Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, Mei-Jie Zhang, Khalid Bo-Subait, Jonathan Sanchez, Hai-Lin Wang, Mahmoud Aljurf, Amer Assal, Vera Ulrike Bacher, Sherif M. Badawy, Nelli Bejanyan, Vijaya Raj Bhatt, Christopher Bredeson, Michael Byrne, Paul Castillo, Jan Cerny, Saurabh Chhabra, Stefan Octavian Ciurea, Zachariah DeFilipp, Nosha Farhadfar, Shahinaz Gadalla, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard Hildebrandt, Christopher G. Kanakry, Ankit Kansagra, Farhad Khimani, Maxwell Krem, Hillard Lazarus, Hongtao Liu, Rodrigo Martino, Fotios V. Michelis, Sunita Nathan, Taiga Nishihori, Richard Olsson, Ran Reshef, David Rizzieri, Jacob M. Rowe, Bipin N. Savani, Sachiko Seo, Akshay Sharma, Melhem Solh, Celalettin Ustun, Leo F. Verdonck, Christopher Hourigan, Brenda Sandmaier, Mark Litzow, Partow Kebriaei, Daniel Weisdorf, Yanming Zhang, Martin S. Tallman, Wael Saber

Blood Adv (2022) 6 (3): 828–847.

https://doi.org/10.1182/bloodadvances.2021004881

Published: 2022

Includes: Supplemental data

Journal Articles

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Chezi Ganzel, Ju-Whei Lee, Hugo F. Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M. Lazarus, Larry D. Cripe, Dan Douer, Peter H. Wiernik, Jacob M. Rowe, Martin S. Tallman, Mark R. Litzow

Blood Adv (2021) 5 (22): 4560–4568.

https://doi.org/10.1182/bloodadvances.2021004999

Published: 2021

Journal Articles

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Anthony F. Daniyan, Christopher Famulare, Bernadette M. Cuello, Troy Z. Horvat, Omar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail Roshal, Martin S. Tallman, Aaron D. Goldberg

Blood Adv (2021) 5 (5): 1552–1564.

https://doi.org/10.1182/bloodadvances.2020003734

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Blood Adv (2021) 5 (2): 504–512.

https://doi.org/10.1182/bloodadvances.2020002439

Published: 2021

Includes: Supplemental data

Journal Articles

A JAK2 / IDH1 -mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Wenbin Xiao, Linde A. Miles, Robert L. Bowman, Vidushi Durani, Helen S. Tian, Nicole L. DelGaudio, Tanmay Mishra, Menglei Zhu, Yanming Zhang, Sarah E. Stump, Martin S. Tallman, Ross L. Levine, Sheng F. Cai

Blood Adv (2020) 4 (23): 6034–6038.

https://doi.org/10.1182/bloodadvances.2020003326

Published: 2020

Journal Articles

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A. Wood, Donna S. Neuberg, J. Colton Thompson, Martin S. Tallman, Mikkael A. Sekeres, Laurie H. Sehn, Kenneth C. Anderson, Aaron D. Goldberg, Nathan A. Pennell, Charlotte M. Niemeyer, Emily Tucker, Kathleen Hewitt, Robert M. Plovnick, Lisa K. Hicks

Blood Adv (2020) 4 (23): 5966–5975.

https://doi.org/10.1182/bloodadvances.2020003170

Published: 2020

Includes: Supplemental data

Journal Articles

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Blood Adv (2020) 4 (19): 4945–4954.

https://doi.org/10.1182/bloodadvances.2020002904

Published: 2020

Includes: Supplemental data

Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg

Blood Adv (2020) 4 (13): 2866–2870.

https://doi.org/10.1182/bloodadvances.2020001482

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

Blood Adv (2020) 4 (9): 1894–1905.

https://doi.org/10.1182/bloodadvances.2020001503

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum

Blood Adv (2020) 4 (8): 1683–1689.

https://doi.org/10.1182/bloodadvances.2019001278

Published: 2020

Journal Articles

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Blood Adv (2019) 3 (24): 4228–4237.

https://doi.org/10.1182/bloodadvances.2019000925

Published: 2019

Includes: Supplemental data

Journal Articles

Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor

Margaret Nieborowska-Skorska, Elisabeth M. Paietta, Ross L. Levine, Hugo F. Fernandez, Martin S. Tallman, Mark R. Litzow, Tomasz Skorski

Blood Adv (2019) 3 (23): 4050–4054.

https://doi.org/10.1182/bloodadvances.2019000756

Published: 2019

Includes: Supplemental data

Journal Articles

Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review

John Y. Rhee, Douglas Tremblay, Amy M. Chan, Martin S. Tallman, John Mascarenhas

Blood Adv (2019) 3 (12): 1854–1857.

https://doi.org/10.1182/bloodadvances.2019000249

Published: 2019

NARROW

Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912

Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A -rearranged AML

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

A JAK2 / IDH1 -mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor

Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only